What Is C15:0 (Pentadecanoic Acid)?
C15:0, or pentadecanoic acid, is a 15-carbon saturated fatty acid belonging to the family of odd-chain fatty acids (OCFAs). While even-chain fatty acids like palmitic acid (C16:0) and stearic acid (C18:0) dominate our dietary fat intake, odd-chain fatty acids are present in much smaller quantities — primarily in dairy products, some ruminant meats, and certain fish.
For decades, odd-chain fatty acids were considered metabolic curiosities with little biological significance. That changed when epidemiological studies began consistently linking higher blood levels of C15:0 with lower rates of type 2 diabetes, cardiovascular disease, and metabolic syndrome. The question became: is C15:0 merely a biomarker of dairy consumption (and therefore a proxy for diet quality), or does it have independent biological activity?
A team of researchers led by Dr. Stephanie Venn-Watson has argued forcefully for the latter, proposing that C15:0 is, in fact, an essential fatty acid — the first to be identified in nearly a century. Their work has resulted in a commercial supplement called Fatty15, which provides pure C15:0 in capsule form.
The hypothesis is bold. Let's evaluate the evidence.
How C15:0 May Work
AMPK Activation
One of the central mechanisms proposed for C15:0's benefits is activation of AMP-activated protein kinase (AMPK), often called the body's "energy sensor." AMPK activation is associated with improved glucose uptake, enhanced fatty acid oxidation, reduced inflammation, and cellular repair processes. Many longevity-promoting interventions — caloric restriction, exercise, metformin, and berberine — share AMPK activation as a common pathway.
In vitro studies have demonstrated that C15:0 activates AMPK in human cell lines, leading to downstream metabolic improvements [1]. However, the concentrations used in cell culture experiments don't always translate directly to what's achievable through oral supplementation in humans.
Anti-Inflammatory Effects
C15:0 has shown anti-inflammatory properties in cell-based studies, reducing levels of pro-inflammatory cytokines including IL-6, IL-8, and MCP-1. Venn-Watson et al. reported that C15:0 reduced inflammatory markers across multiple human cell systems at physiologically relevant concentrations [1].
Chronic low-grade inflammation is a hallmark of aging (sometimes called "inflammaging") and is implicated in virtually every major age-related disease. If C15:0 can meaningfully reduce systemic inflammation in humans, the downstream health implications would be significant.
Cell Membrane Stabilization
C15:0 is a fully saturated fatty acid, meaning it has no double bonds in its carbon chain. This gives it structural rigidity, which may help stabilize cell membranes — particularly in the context of age-related membrane fragility. The proposed mechanism is that C15:0 integrates into phospholipid bilayers, improving membrane integrity and reducing susceptibility to lipid peroxidation.
This is an interesting hypothesis supported by biophysical modeling, but direct evidence of clinically meaningful membrane stabilization from C15:0 supplementation in humans is still lacking.
PPARα/δ Agonism
C15:0 has been identified as an agonist of peroxisome proliferator-activated receptors (PPARs), specifically PPARα and PPARδ. These nuclear receptors regulate genes involved in lipid metabolism, glucose homeostasis, and inflammation. Pharmaceutical PPARα agonists (fibrates) are used to treat dyslipidemia, so a dietary compound with similar activity would be of considerable interest.
The PPAR agonism data comes primarily from cell-based assays and needs confirmation in human pharmacokinetic and pharmacodynamic studies.
C15:0 Benefits: What the Research Shows
Epidemiological Evidence
The strongest evidence for C15:0's health relevance comes from large observational studies. Multiple prospective cohorts have found that higher circulating levels of C15:0 are associated with:
- Lower risk of type 2 diabetes — A meta-analysis of prospective studies found that each standard deviation increase in blood C15:0 was associated with a 25–35% lower risk of developing type 2 diabetes.
- Reduced cardiovascular mortality — The EPIC-InterAct study and others have linked higher C15:0 levels with lower all-cause and cardiovascular mortality.
- Better metabolic health markers — Including lower fasting glucose, lower triglycerides, higher HDL cholesterol, and smaller waist circumference.
However, a critical caveat applies: blood levels of C15:0 are strongly correlated with dairy fat consumption. It remains possible (some would say likely) that C15:0 is primarily a biomarker of overall dietary patterns rather than a causative protective agent. People who consume moderate amounts of dairy may differ from non-consumers in many ways — diet quality, socioeconomic status, lifestyle factors — that independently affect metabolic health.
Cell-Based and Preclinical Studies
Venn-Watson et al. (2020) published a pivotal study in *Scientific Reports* demonstrating that C15:0 repaired cell damage across 12 human cell systems modeling various disease states, outperforming omega-3 EPA (eicosapentaenoic acid) in several comparisons [2]. The study showed C15:0 reducing markers of inflammation, fibrosis, and anemia while improving mitochondrial function.
This was a well-conducted in vitro study, but comparing a novel compound to EPA in cell culture doesn't automatically mean C15:0 is superior in living humans. Cell-based studies lack the complexity of whole-body metabolism, absorption, distribution, and excretion.
The "Essential Fatty Acid" Argument
In a 2023 review, Venn-Watson and colleagues formally proposed that C15:0 meets the criteria for an essential fatty acid [1]. Their argument rests on several points:
1. The body cannot synthesize C15:0 efficiently (it must come from diet)
2. C15:0 deficiency is associated with disease states
3. Restoring C15:0 levels reverses cellular dysfunction in vitro
4. C15:0 acts through specific, identified biological receptors
The proposal is intellectually interesting but has not been endorsed by mainstream nutrition science bodies. The criteria for "essential" status are rigorous — typically requiring demonstration that deficiency causes a specific disease that is reversed by supplementation. No such definitive deficiency syndrome has been identified for C15:0 in humans.
Human Supplementation Data
As of early 2026, published human interventional studies specifically examining oral C15:0 supplementation are limited. The Fatty15 company has conducted internal studies, and some data has been published or presented at conferences, but large, independent, peer-reviewed randomized controlled trials are still forthcoming.
This is the biggest gap in the evidence. We have compelling epidemiological associations, interesting cell-based data, and a plausible mechanistic story — but we're missing the definitive clinical trials that would confirm whether taking a C15:0 supplement actually improves health outcomes in humans.
Dosage and How to Take C15:0
The primary commercial supplement (Fatty15) provides 100 mg of pure C15:0 per capsule, taken once daily. Some protocols suggest 200–300 mg per day for initial loading phases.
Dietary sources of C15:0 include:
- Whole milk and full-fat dairy products
- Butter
- Certain cheeses (particularly from grass-fed ruminants)
- Some fish species
However, getting 100+ mg of pure C15:0 from diet alone would require substantial dairy intake, which is why supplementation has been proposed as a more targeted approach.
Timing: C15:0 is fat-soluble and likely best absorbed with a meal containing some dietary fat. No specific time-of-day recommendation has been established.
Safety and Side Effects
C15:0 appears to have a favorable safety profile based on available data:
- It is a naturally occurring component of common foods (dairy, fish)
- Toxicological studies have not identified concerning effects at supplemental doses
- No significant adverse events have been reported in published human trials
- It is a saturated fatty acid, but odd-chain saturated fats behave differently from the even-chain saturated fats associated with cardiovascular risk
Potential concerns:
- Long-term safety of supplemental C15:0 has not been established in large populations
- Individuals with dairy allergies should note that while pure C15:0 supplements don't contain dairy proteins, some may prefer to verify with manufacturers
- Interactions with lipid-lowering medications are theoretically possible given PPAR agonism, though none have been reported
Limitations and Honest Assessment
Let's be direct about where the C15:0 story stands:
What's strong:
- Consistent epidemiological associations between blood C15:0 levels and reduced metabolic disease risk
- Plausible and multi-pathway biological mechanisms (AMPK, PPARs, anti-inflammatory)
- Favorable safety profile
- The basic science is conducted by credentialed researchers and published in peer-reviewed journals
What's weak:
- Very limited human interventional data from independent researchers
- The essential fatty acid claim is a hypothesis, not an established fact
- The primary research group has significant commercial interests (Fatty15)
- Epidemiological data cannot establish causation — C15:0 may be a biomarker, not a driver
- Cell culture results don't reliably predict human supplement outcomes
- No head-to-head clinical trials comparing C15:0 supplementation against established interventions
The Verdict
C15:0 is one of the more intellectually interesting supplements to emerge in the longevity space. The epidemiological data linking higher C15:0 levels to better metabolic outcomes is genuinely robust, the proposed mechanisms are biologically plausible, and the safety profile appears clean.
However, the leap from "higher blood levels correlate with better health" to "supplementing with C15:0 will improve your health" is exactly the kind of assumption that has led many promising nutritional hypotheses astray (remember the beta-carotene story?). The claims are currently ahead of the evidence.
Who might consider trying it:
- Longevity enthusiasts willing to be early adopters of emerging science
- People with low dairy intake who may have genuinely low C15:0 levels
- Those interested in metabolic health optimization with a favorable risk–benefit ratio
Who should wait:
- Anyone looking for proven interventions with strong clinical trial support
- Those on tight supplement budgets (Fatty15 costs ~$50/month)
- People who already consume moderate amounts of full-fat dairy
C15:0 is a hypothesis worth tracking. The next 2–3 years of independent clinical research will determine whether it lives up to its considerable promise.